ReviewESMO open2025
A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be addressed?
Review in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychological interventions to alleviate death anxiety among patients with cancer: a systematic review and meta-analysis of randomized controlled studies.BMC psychology · 2026Pooled it
- Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers.The oncologist · 2026Article
- Hope and despair in cancer and other illnesses: a clinical framework for adaptive hope across the illness trajectory.ESMO open · 2026Review
- More than survival curves: why every oncologist has to read this article on adaptive hope.ESMO open · 2026Article
- Cancer-Directed Therapy in the Last Month of Life and Its Association With ICU Utilisation in a Tertiary Care Centre in India.Cancer medicine · 2026Article
- The Influence of Specialist Palliative Care in Aggressive End of Life Management of Patients with Advanced Cancer.Zdravstveno varstvo · 2026Article
- Article
- Oncology with common sense: beyond biologistic and pharmacological models.Ecancermedicalscience · 2026Article
- Less is more: inverting the paradigm across the cancer care continuum.EClinicalMedicine · 2025Review
- What is the role of common sense oncology in the Western Pacific?The Lancet regional health. Western Pacific · 2025Review
- Article
- Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with cancer approaching the end of life (EOL) continue to receive treatments that are unlikely to provide meaningful clinical benefit, potentially causing more harm than good. This is called overtreatment at the EOL. Overtreatment harms patients by causing side-effects, increasing health care costs, delaying important discussions about and preparation for EOL care, and occasionally accelerating death. Overtreatment can also strain health care resources, reducing those available for palliative care services, and cause moral distress for clinicians and treatment teams. This article reviews the factors contributing to the overtreatment of patients with cancer at the EOL. It addresses the complex range of social, psychological, and cognitive factors affecting oncologists, patients, and patients' family members that contribute to this phenomenon. This intricate and complex dynamic complicates the task of reducing overtreatment. Addressing these driving factors requires a cooperative approach involving oncologists, oncology nurses, professional societies, public policy, and public education. We therefore discuss approaches and strategies to mitigate cultural and professional influences driving overtreatment, reduce the seduction of new technologies, improve clinician-patient communication regarding therapeutic options for patients approaching the EOL, and address cognitive biases that can contribute to overtreatment at the EOL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.